HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Subramanian Hariharan Selected Research
Subramanian Hariharan Research Topics
Disease
19
Renal Cell Carcinoma (Grawitz Tumor)
10/2022 - 01/2009
14
Neoplasms (Cancer)
01/2022 - 08/2002
4
Disease Progression
01/2019 - 08/2002
3
Merkel Cell Carcinoma
01/2020 - 01/2017
2
Hypertension (High Blood Pressure)
05/2013 - 05/2011
2
Fatigue
05/2013 - 03/2012
1
Dyslipidemias (Dyslipidemia)
10/2022
1
Infections
01/2022
1
COVID-19
01/2022
1
Body Weight (Weight, Body)
01/2019
1
Adrenocortical Carcinoma
10/2018
1
Carcinoma (Carcinomatosis)
01/2018
1
Myocarditis (Carditis)
01/2018
1
Non-Muscle Invasive Bladder Neoplasms
01/2018
1
Myocardial Infarction
12/2015
1
Edema (Dropsy)
12/2015
1
Proteinuria
12/2015
1
Hypercholesterolemia
03/2014
1
Neutropenia
03/2014
1
Pneumonia (Pneumonitis)
03/2014
1
Hyperglycemia
03/2014
1
Hypophosphatemia
03/2014
1
Stomatitis
03/2014
1
Inflammation (Inflammations)
03/2014
1
Hand-Foot Syndrome
05/2013
1
Clear-cell metastatic renal cell carcinoma
05/2013
1
Brain Neoplasms (Brain Tumor)
02/2011
1
Cardiotoxicity
04/2008
1
Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2006
1
Small Cell Lung Carcinoma (Small Cell Lung Cancer)
05/2006
1
Meningioma (Meningiomas)
08/2002
1
Glioblastoma (Glioblastoma Multiforme)
05/2002
Drug/Important Bio-Agent (IBA)
15
Sunitinib (Sutent)
FDA Link
10/2022 - 04/2008
6
Axitinib (AG 013736)
IBA
10/2022 - 05/2013
6
avelumab
IBA
10/2022 - 01/2017
5
B7-H1 Antigen
IBA
01/2020 - 01/2017
4
Immune Checkpoint Inhibitors
IBA
10/2022 - 01/2017
4
Biomarkers (Surrogate Marker)
IBA
10/2022 - 05/2011
3
Sorafenib (BAY 43-9006)
FDA Link
10/2014 - 09/2011
2
Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
IBA
10/2022 - 10/2014
2
Monoclonal Antibodies
IBA
01/2020 - 01/2018
2
Cisplatin (Platino)
FDA Link
Generic
01/2018 - 05/2006
2
Antibodies
IBA
01/2018 - 01/2017
2
Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
IBA
10/2017 - 05/2011
2
temsirolimus
FDA Link
10/2014 - 03/2014
2
Tyrosine Kinase Inhibitors
IBA
10/2014 - 01/2009
2
Interferon-alpha (Interferon Alfa)
IBA
03/2014 - 01/2009
2
Bevacizumab (Avastin)
FDA Link
03/2014 - 09/2011
2
Interferons
IBA
09/2011 - 01/2009
2
Irinotecan (Camptosar)
FDA Link
Generic
10/2006 - 05/2006
1
omega-Chloroacetophenone (Mace)
IBA
10/2022
1
Messenger RNA (mRNA)
IBA
01/2022
1
Vaccines
IBA
01/2022
1
BNT162 Vaccine
IBA
01/2022
1
COVID-19 Vaccines
IBA
01/2022
1
Ligands
IBA
11/2020
1
Immunoglobulins (Immunoglobulin)
IBA
01/2020
1
Platinum
IBA
01/2018
1
pembrolizumab
IBA
01/2017
1
Creatinine
IBA
12/2015
1
Amylases
FDA Link
12/2015
1
TOR Serine-Threonine Kinases
IBA
10/2014
1
Gemcitabine
FDA Link
10/2006
1
Docetaxel (Taxotere)
FDA Link
10/2006
1
Celecoxib (Celebrex)
FDA Link
10/2006
1
Etoposide (VP 16)
FDA Link
Generic
05/2006
1
Hydroxyurea (Hydrea)
FDA Link
Generic
08/2002
Therapy/Procedure
11
Therapeutics
10/2022 - 08/2002
3
Drug Therapy (Chemotherapy)
01/2018 - 08/2002
1
Immunotherapy
01/2018
1
Nephrectomy
03/2014
1
Aftercare (After-Treatment)
03/2012
1
Duration of Therapy
08/2002
1
Radiotherapy
08/2002
1
Craniotomy
05/2002